Mammaglobin A

Ghersevich, Sergio; Ceballos, María Paula

doi:10.1016/b978-0-12-800263-6.00006-9

Cited by 15 publications

(3 citation statements)

References 113 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Mammaglobin-A is an 8- to 25-kDa protein, depending on various types of posttranslational processing and modification, the genetic sequence of which was first isolated in 1994. 38 Although the biological role of mammaglobin-A is still unknown, it is a member of the secretoglobin family, has expression largely limited to the breast gland, and is overexpressed in 80 percent of primary breast cancers, making it a prime target for breast cancer therapy. 39 Studies in mice with mammaglobin-A–expressing tumors have shown tumor regression after mammaglobin-A vaccination, suggesting that mammaglobin-A drives persistence and/or progression of tumors.…”

Section: Discussionmentioning

confidence: 99%

Can Breast Implants Induce Breast Cancer Immunosurveillance? An Analysis of Antibody Response to Breast Cancer Antigen following Implant Placement

Fracol

Shah

Dolivo

et al. 2021

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

Background: Women with cosmetic breast implants have significantly lower rates of subsequent breast cancer than the general population (relative risk, 0.63; 95 percent CI, 0.56 to 0.71). The authors hypothesize that breast implant-induced local inflammation stimulates immunosurveillance recognition of breast tumor antigen. Methods: Sera were collected from two cohorts of healthy women: women with long-term breast implants (i.e., breast implants for >6 months) and breast implant-naive women. Antibody responses to breast tumor antigens were tested by enzyme-linked immunosorbent assay and compared between cohorts by unpaired t test. Of the implant-naive cohort, nine women underwent breast augmentation, and antibody responses before and after implant placement were compared by paired t test. Results: Sera were collected from 104 women: 36 (34.6 percent) long-term breast implants and 68 (65.4 percent) implant-naive women. Women with long-term breast implants had higher antibody responses than implant-naive women to mammaglobin-A (optical density at 450 nm, 0.33 versus 0.22; p = 0.003) and mucin-1 (optical density at 450 nm, 0.42 versus 0.34; p = 0.02). There was no difference in antibody responses to breast cancer susceptibility gene 2, carcinoembryonic antigen, human epidermal growth factor receptor-2, or tetanus. Nine women with longitudinal samples preoperatively and 1 month postoperatively demonstrated significantly elevated antibody responses following implant placement to mammaglobin-A (mean difference, 0.13; p = 0.0002) and mucin-1 (mean difference 0.08; p = 0.02). There was no difference in postimplant responses to other breast tumor antigens, or tetanus. Conclusions: Women with long-term breast implants have higher antibody recognition of mammaglobin-A and mucin-1. This study provides the first evidence of implant-related immune responses to breast cancer antigens. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, V.

show abstract

Section: Discussionmentioning

confidence: 99%

Can Breast Implants Induce Breast Cancer Immunosurveillance? An Analysis of Antibody Response to Breast Cancer Antigen following Implant Placement

Fracol

Shah

Dolivo

et al. 2021

Plastic &Amp; Reconstructive Surgery

View full text Add to dashboard Cite

show abstract

“…MAM-A is a gene expressed almost exclusively in normal breast epithelium and human breast cancer, which is a potential immunotherapeutic target against breast cancer. [41] MSLN is a cell surface antigen implicated in tumor invasion, which is highly expressed in mesothelioma, lung, pancreatic, breast, ovarian, and other cancers, [42,43] and lowly expressed in normal mesothelial cells, which it is a potential target for cancer immunotherapy. [44]…”

Section: Differentiation-specific Antigensmentioning

confidence: 99%

Advances in Tumor Antigen‐Based Anticancer Immunotherapy: Recent Progress, Prevailing Challenges, and Future Perspective

Shi

Chen

Chi

et al. 2022

Advanced Therapeutics

View full text Add to dashboard Cite

Elimination of tumors by regulating the immune system is the primary research focus in the rapidly developing field of immune-oncology. Current immunotherapeutic strategies mainly include immune checkpoint blockade therapy, adoptive immune cell therapy, and cancer vaccines. Among them, tumor antigen-based cancer vaccines can potentially elicit specific and potent anti-tumor immune responses with less toxicity and side effects, which are recognized as promising treatments in immunotherapy. The selection of tumor antigens is the primary determinant of cancer vaccine design, whereas systematic reviews based on them are scarce. In the present review, currently known tumor antigens and recent developments in cancer vaccines based on tumor antigens, including traditional antigen vaccines, neoantigen vaccines, shared antigen vaccines, and oral antigen vaccines, in hopes of providing fundamental basis for further development of novel cancer vaccine-based therapies, are summarized.

show abstract

“…Detection of molecular markers specific to cancer cells or tissues in CTC could enhance prognostic information in breast cancer patients. However, several markers identified in CTC obtained from breast cancer patients, such as cytokeratin, CEA, mucin 1, EpCAM and human epidermal growth factor receptor 2 [1,6] lack sufficient sensitivity and specificity for detecting breast cancer CTC [7], with the exception of mammaglobin (SCGB2A2), which is a member of the uteroglobin protein family [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

Relationship between Human Mammaglobin mRNA in Peripheral Blood and Overall Survival in Breast Cancer Patients: A Systematic Review and Meta-Analysis

Kim¹,

Ahn²,

Ahn³

et al. 2017

J Oncol Transl Res

View full text Add to dashboard Cite

Mammaglobin A

Cited by 15 publications

References 113 publications

Can Breast Implants Induce Breast Cancer Immunosurveillance? An Analysis of Antibody Response to Breast Cancer Antigen following Implant Placement

Can Breast Implants Induce Breast Cancer Immunosurveillance? An Analysis of Antibody Response to Breast Cancer Antigen following Implant Placement

Advances in Tumor Antigen‐Based Anticancer Immunotherapy: Recent Progress, Prevailing Challenges, and Future Perspective

Relationship between Human Mammaglobin mRNA in Peripheral Blood and Overall Survival in Breast Cancer Patients: A Systematic Review and Meta-Analysis

Contact Info

Product

Resources

About